OBJECTIVE: The relationship between cannabis use and psychosis has been studied intensively. Few data, however, are available on the relationship between cannabis use, ultra-high risk for developing psychosis and neurocognition. The aim of the present cross-sectional study was therefore to investigate the relationship between cannabis use, ultra-high-risk (UHR) symptoms and cognitive functioning in UHR patients and healthy controls. METHODS: A total of 63 ultra-high-risk patients (34 cannabis users) and 58 control subjects (28 cannabis users) were assessed with clinical measures and a neuropsychological test battery. Patients were eligible for the study if they were between the ages of 12 and 35 years and if they fell into one or more of the following inclusion groups: familial risk and reduced functioning, attenuated psychotic symptoms, brief limited intermittent psychotic symptoms and basic symptoms. Control subjects were eligible for the study if they were between the ages 12 and 35, had no present or past psychiatric illness, no family history of psychiatric illness, no drug use in the non-cannabis-using group, and use of at least four joints per week in the cannabis-using control group. RESULTS: In the UHR and the control group, cannabis users experienced more basic symptoms and UHR symptoms than the non-cannabis users. Moreover, cannabis users in the control group performed at the level of the UHR subjects on a test of verbal memory and verbal fluency. Frequency of cannabis use correlated with severity of several UHR symptoms. CONCLUSIONS: Cannabis-using UHR patients have more basic symptoms than non-using patients. In addition, healthy cannabis users have more subclinical UHR and basic symptoms and more neuropsychological dysfunctions than non-cannabis users. More frequent cannabis use was related to increased severity of certain UHR symptoms.
OBJECTIVE: The relationship between cannabis use and psychosis has been studied intensively. Few data, however, are available on the relationship between cannabis use, ultra-high risk for developing psychosis and neurocognition. The aim of the present cross-sectional study was therefore to investigate the relationship between cannabis use, ultra-high-risk (UHR) symptoms and cognitive functioning in UHR patients and healthy controls. METHODS: A total of 63 ultra-high-risk patients (34 cannabis users) and 58 control subjects (28 cannabis users) were assessed with clinical measures and a neuropsychological test battery. Patients were eligible for the study if they were between the ages of 12 and 35 years and if they fell into one or more of the following inclusion groups: familial risk and reduced functioning, attenuated psychotic symptoms, brief limited intermittent psychotic symptoms and basic symptoms. Control subjects were eligible for the study if they were between the ages 12 and 35, had no present or past psychiatric illness, no family history of psychiatric illness, no drug use in the non-cannabis-using group, and use of at least four joints per week in the cannabis-using control group. RESULTS: In the UHR and the control group, cannabis users experienced more basic symptoms and UHR symptoms than the non-cannabis users. Moreover, cannabis users in the control group performed at the level of the UHR subjects on a test of verbal memory and verbal fluency. Frequency of cannabis use correlated with severity of several UHR symptoms. CONCLUSIONS: Cannabis-using UHR patients have more basic symptoms than non-using patients. In addition, healthy cannabis users have more subclinical UHR and basic symptoms and more neuropsychological dysfunctions than non-cannabis users. More frequent cannabis use was related to increased severity of certain UHR symptoms.
Authors: Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Moogeh Baharnoori; Cali Bartholomeusz; Aurelie A Boucher; Lisa Buchy; Christopher Chaddock; Bonga Chiliza; Melanie Föcking; Alex Fornito; Juan A Gallego; Hiroaki Hori; Gisele Huf; Gul A Jabbar; Shi Hyun Kang; Yousri El Kissi; Jessica Merchán-Naranjo; Gemma Modinos; Nashaat A M Abdel-Fadeel; Anna-Karin Neubeck; Hsiao Piau Ng; Gabriela Novak; Olasunmbo O Owolabi; Diana P Prata; Naren P Rao; Igor Riecansky; Darryl C Smith; Renan P Souza; Renate Thienel; Hanan D Trotman; Hiroyuki Uchida; Kristen A Woodberry; Anne O'Shea; Lynn E DeLisi Journal: Schizophr Res Date: 2010-10-08 Impact factor: 4.939
Authors: A M Auther; K S Cadenhead; R E Carrión; J Addington; C E Bearden; T D Cannon; T H McGlashan; D O Perkins; L Seidman; M Tsuang; E F Walker; S W Woods; B A Cornblatt Journal: Acta Psychiatr Scand Date: 2015-01-09 Impact factor: 6.392
Authors: Yun Lu; Catherine Marshall; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel Mathalon; Jean Addington Journal: Psychiatry Res Date: 2017-08-31 Impact factor: 3.222
Authors: H Bugra; E Studerus; C Rapp; C Tamagni; J Aston; S Borgwardt; A Riecher-Rössler Journal: Psychopharmacology (Berl) Date: 2013-06-12 Impact factor: 4.530
Authors: Jean Addington; Nevicia Case; Majid M Saleem; Andrea M Auther; Barbara A Cornblatt; Kristin S Cadenhead Journal: Early Interv Psychiatry Date: 2013-11-14 Impact factor: 2.732